{
  "docId": "019de075-8d44-7401-b489-ee436db9a207",
  "docSlug": "66ec60e76d61a423395d466c32dc56fb",
  "documentTitle": "Exscientia | Investor Presentation Deck | 75 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 65,
  "pageCount": 75,
  "prevPage": 64,
  "nextPage": 66,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Scientific/medical context slide explaining a therapeutic target.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8d44-7401-b489-ee436db9a207/65",
  "deckHref": "/decks/019de075-8d44-7401-b489-ee436db9a207",
  "deckJsonHref": "/decks/019de075-8d44-7401-b489-ee436db9a207.json",
  "deckAnchorHref": "/decks/019de075-8d44-7401-b489-ee436db9a207#slide-65",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.85,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "BCR signalling pathway is chronically activated in some haematologic indications through multiple mechanisms\nMALT1 is a key component of dysregulated antigen signalling pathways in T- and B-cell malignancies\nProtease activity crucial for activation of the NF-κB pathway\nSupports uncontrolled proliferation of malignant T- and B-cells in haematological cancers\nMALT1 inhibition can block/dampen NF-κB signalling which is activated in DLBCL subtypes\nSingle agent treatments currently used in a subtype of DLBCL are generally not curative/drive resistance\nCombining MALT1 inhibition with BTK inhibitors (or BCL2 inhibitors) may achieve deep and long duration of response and enable treatment cessation upon attainment of undetectable minimal residual disease in CLL",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cf941f8-7502-4fbd-a357-04a40b7bac7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Important mechanism in haematologic malignancies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67537637-da07-4326-ac21-6f0d86dbac38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "MALT1: Inhibition of immune cell signalling",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e652ba1f-91fc-4a64-91bf-24e20e14c687",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "8b087121-9d41-4f83-85a0-d2dd4562ebb9",
      "evidence": "BCR signalling pathway is chronically activated in some haematologic indications through multiple mechanisms",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}